Dr. Petrocca is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
830 Harrison Ave
# Moakley
Boston, MA 02118Phone+1 617-638-6428Fax+1 617-638-5756
Education & Training
Sapienza University of RomeClass of 2004
Certifications & Licensure
MA State Medical License 2020 - 2025
Publications & Presentations
PubMed
- Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis.Maya Abdallah, Frances Arters, Jasmine Patel, Camille Edwards, Adam Lerner
Blood Advances. 2024-12-10 - 35 citationsIdecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.Yi Lin, Noopur S Raje, Jesús G Berdeja, David S Siegel, Sundar Jagannath
Nature Medicine. 2023-09-01 - 193 citationsBiallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.Mehmet Kemal Samur, Mariateresa Fulciniti, Anil Aktas Samur, Abdul Hamid Bazarbachi, Yu-Tzu Tai
Nature Communications. 2021-02-08
Journal Articles
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine
Press Mentions
How Boston Is Beating CancerJanuary 24th, 2023- BMC Is Poised to Enter the CAR T-cell Therapy Clinical Trials EcosystemJanuary 12th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
